Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury

Journal of Neurotrauma

Volumn 15, Issue 10, 1998, Pages 837-849

  Potter, P J ^a   Hayes, K C ^a,e   Segal, J L ^b   Hsieh, J T C ^a   Brunnemann, S R ^b   Delaney, G A ^a   Tierney, D S ^c   Mason, D ^d  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c Elan Pharmaceutical Research Corporation   (United States)

^d Athena Neurosciences Inc   (United States)

^e PARKWOOD HOSPITAL   (Canada)

Author keywords

4 aminopyridine; Fampridine; Spinal cord injury

Indexed keywords

4 AMINOPYRIDINE; POTASSIUM CHANNEL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; NAUSEA; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NERVE; SPINAL CORD INJURY; SUSTAINED RELEASE PREPARATION; VERTIGO;

EID: 0031793091     PISSN: 08977151     EISSN: None     Source Type: Journal    
DOI: 10.1089/neu.1998.15.837     Document Type: Article

References (65)

1. ANDREWS, F.M., and WITHEY, S.B. (1976). Social Indicators of Well-Being: Americans' Perceptions of Life Quality. Plenum Press: New York.
2. BAKER, M., BOSTOCK, H., GRAFE, P., and MARTIUS, P. (1987). Function and distribution of three types of rectifying channel in the rat spinal root myelinated axons. J. Physiol. (Lond.) 38, 345-367.
3. BEVER, C.T., JR. (1994). The current status of studies of aminopyridines in patients with multiple sclerosis. Ann. Neurol. 36, Suppl., S118-S121.
4. BEVER, C.T., JR., YOUNG, D., ANDERSON, P.A., et al. (1994). The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 44, 1054-1059.
5. BLIGHT, A.R. (1989). Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury. Brain Res. Bull. 22, 47-52.
6. BLIGHT, A.R., and GRUNER, J.A. (1987). Augmentation by 4-aminopyridine of vestibulospinal free fall responses in chronic spinal-injured cats. J. Neurol. Sci. 87, 145-159.
7. BLIGHT, A.R., TOOMBS, J.P., BAUER, M.S., and WIDMER, W.R. (1991). The effects of 4-aminopyridine on neurological deficits in chronic cases of traumatic spinal cord injury in dogs: a Phase I clinical trial. J. Neurotrauma 8, 103-119.
8. BOHANNON, R.W., and SMITH, M.B. (1987). Interrater reliability on a modified Ashworth scale of muscle spasticity. Phys. Ther. 67, 106-107.
9. BOSTOCK, H., SEARS, T.A., and SHERRATT, R.M. (1981). The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J. Physiol. (Lond.) 313, 301-315.
10. BOWE, C.M., KOCSIS, J.D., TARG, E.F., and WAXMAN, S.G. (1987). Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers. Ann. Neurol. 22, 264-268.
11. COLTON, T. (1974). Statistics in Medicine. Little, Brown and Company: Boston.
12. COURTOIS, F.J., CHARVRIER, K.F., LERICH, A., and RAYMOND, D.P. (1993). Sexual function in spinal cord injury men. I. Assessing sexual capability. Paraplegia 31, 771-784.
13. DAVIS, F.A., STEFOSKI, D., and RUSH, J. (1990). Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol. 27, 186-192.
14. DAVIS, F.A., STEFOSKI, D., and QUANDT, F.N. (1995). Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis. Ann. Neurol. 37, 684.
15. DITUNNO, J.F., YOUNG, W., DONOVAN, W.H., and CREASEY, G. (1994). The International Standards booklet for neurological and functional classification of spinal cord injury. Paraplegia 32, 70-80.
16. ENGLAND, J.D., HAPPEL, L.T., KLINE, D.G., et al. (1996). Sodium channel accumulation in humans with pain neuromas. Neurology 47, 272-276.
17. FASTIER, F.N., and McDOWALL, M.A. (1958). Analgesic activity of 4-methyl-2-aminopyridine and of some related compounds. Aust. J. Biol. Sci. 36, 491-498.
18. FEHLINGS, M.G., and NASHMI, R. (1996). Changes in pharmacological sensitivity of the spinal cord to potassium channel blockers following acute spinal cord injury. Brain 736, 135-145.
19. GORDON, T.R., KOCSIS, J.D., and WAXMAN, S.G. (1988). Evidence for the presence of two types of potassium channels in the rat optic nerve. Brain Res. 447, 1-9.
20. GRANGER, C.V., and HAMILTON, B.B. (1993). The uniform data system for medical rehabilitation: report of first admissions for 1991. Am. J. Phys. Med. Rehabil. 72, 33-38.
21. HAGHIGHI, S.S., PUGH, S.L., PEREZ-ESPEJO, M.A., and ORO, J.J. (1995). Effect of 4-aminopyridine in acute spinal cord injury. Surg. Neurol. 43, 443-447.
22. HANSEBOUT, R.R., BLIGHT, A.R., FAWCETT, S., and REDDY, K. (1993). 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J. Neurotrauma 10, 1-8.
23. HAYES, K.C. (1994). 4-Aminopyridine and spinal cord injury: a review. Restor. Neurol. Neurosci. 6, 259-270.
24. HAYES, K.C., BLIGHT, A.R., POTTER, P.J., et al. (1993). Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia 31, 216-224.
25. HAYES, K.C., POTTER, P.J., WOLFE, D.L., HSIEH, I.T.C., DELANEY, G.A., and BLIGHT, A.R. (1994). 4-aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J. Neurotrauma 11, 433-446.
26. JANKOWSKA, E., LUNDBERG, A., RUDOMIN, P., and SYKOVA, E. (1977). Effects of 4-aminopyridine on transmission in excitatory and inhibitory synapses in the spinal cord. Brain Res. 136, 387-388.
27. JANKOWSKA, E., LUNDBERG, A., RUDOMIN, P., and SYKOVA, E. (1982). Effects of 4-aminopyridine on synaptic transmission in the cat spinal cord. Brain Res. 240, 117-129.
28. JONES, R.E., HERON, J.R., FOSTER, D.H. SNELGAR, R.S., and MASON, R.J. (1983). Effects of 4-aminopyridine in patients with multiple sclerosis. J. Neurol. Sci. 60, 353-362.
29. KIM, Y.I., GOLDNER, M.M., and SANDERS, D.B. (1980). Facilitatory effects of 4-aminopyridine on normal neuromuscular transmission. Muscle Nerve 3, 105-111.
30. KIRCHHOFF, C., LEAK, J.D., JUNG, S., and REEH, P.W. (1992). Excitation of cutaneous sensory nerve endings in the rat by 4-aminopyridine and tetraethylammonium. J. Neurophysiol. 67, 125-131.
31. KOCSIS, J.D. (1985). Aminopyridine sensitivity of spinal cord white matter studied in vitro. Exp. Brain Res. 57, 620-624.
32. KOCSIS, J.D., BOWE, C.M., and WAXMAN, S.G. (1986). Different effects of 4-aminopyridine on sensory and motor fibers: pathogenesis of paresthesias. Neurology 36, 117-120.
33. LEMEIGNAN, M. (1972). Analysis of the action of 4-aminopyridine on the cat lumbar spinal cord. I. Modification of the afferent volley, the monosynaptic discharge, amplitude and the polysynaptic evoked responses. Neuropharmacology 11, 551-558.
34. LEMEIGNAN, M. (1973). Analysis of the effect of 4-aminopyridine on the lumbar spinal cord of the cat. II. Modification of certain spinal inhibitory phenomena post-tetanic potentiation and dorsal root potential. Neuropharmacology 12, 641-651.
35. LUNDH, H., and THESLEFF, S. (1977). The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals. Eur. J. Pharmacol. 42, 411-412.
36. LUNDH, H. NILSSON, O., and ROSEN, I. (1979). Effects of 4-aminopyridine in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 42, 171-175.
37. McNEMAR, Q. (1947). Note on the sampling error of the differences between correlated proportions or percentages. Psychometrika 12, 153-157.
38. MELZACK, R. (1975). The McGill Pain Questionnaire: major properties and scoring methods. Pain 1, 277-299.
39. MOLGO, J., LUNDH, H., and THESLEFF, S. (1980). Potency of 3,4diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmissions and the effect of pH changes. Eur. J. Pharmacol. 61, 25.
40. MOLGO, J., LEMEIGNAN, M., and LECHAT, P. (1977). Effects of 4-aminopyridine at the frog neuromuscular junction. J. Pharmacol. Exp. Ther. 203, 653-663.
41. MURRAY, N.M.F., and NEWSOM-DAVIS, J. (1981). Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 31, 265-271.
42. PENN, R.D., SAVOY, S.M., CORCOS, D., et al. (1989). Intrathecal Baclofen for severe spinal spasticity. N. Engl. J. Med. 321, 1517-1521.
43. POLMAN, C.H., BERTELSMANN, F.W., VAN LOENEN, A.C., and KOETSIER, J.C. (1994a). 4-Aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety. Arch. Neurol. 51, 292-296.
44. POLMAN, C.H., BERTELSMANN, F.W., DE WAAL, R., et al. (1994b). 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch. Neurol. 51, 1136-1139.
45. POTTER, P.J., HAYES, K.C., HSIEH, J.T.C., DELANEY, G.A., and SEGAL, J.L. (1998). Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: 3 cases. Spinal Cord 36, 147-155.
46. PRATT, K., TOOMBS, J.P., WIDMER, W.R., and BORGENS, R.B. (1995). Plasma and cerebrospinal fluid concentrations of 4-aminopyridine following intravenous injection and metered intrathecal delivery in canines. J. Neurotrauma 12, 23-39.
47. QIAO, J., HAYES, K.C., HSIEH, J.T.C., POTTER, P.J., and DELANEY, G. A. (1997). Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury. J. Neurotrauma 14, 135-149.
48. SAADE, N., JABBUR, S.J., and WALL, P.D. (1985). Effects of 4-aminopyridine, GABA and bicuculline on cutaneous receptive fields of cat dorsal horn neurons. Brain Res. 344, 356-359.
49. SAADE, N.E., BANNA, N.R., KHOURY, A., JABBUR, S.J., and WALL, P.D. (1982). Cutaneous receptive field alterations induced by 4-aminopyridine. Brain Res. 232, 177-180.
50. SAADE, N.E., CHANELET, J., and LONCHAMPT, P. (1971). Action facilitratrice de microinjection de 4-aminopyridine sur les activities medullaries reflexes de la Grenouille. C. R., Soc. Biol. 165, 2069-2078.
51. SCHWID, S.R., PETRIE, M.D., McDERMOTT, M.P., TIERNEY, D.S., MASON, D.H., and GOODMAN, A.D. (1977). Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology 48, 817-821.
52. SEGAL, J.L. (1995). Clinical pharmacology of spinal cord injury, in: Diagnosis and Management of Disorders of the Spinal Cord. R.R. Young and R.M. Woolsey (eds), W.B. Saunders Co.: Philadelphia, pps. 414-438.
53. SEGAL, J.L. and BRUNNEMANN, S.R. (1997). 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury. Pharmacotherapy 17, 415-423.
54. SEGAL, J.L., and BRUNNEMANN, S.R. (in press). 4-aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans. J Spinal Cord Med.
55. SHERRATT, R.M., BOSTOCK, H., and SEAR, T.A. (1980). Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibers. Nature 283, 570-572.
56. SHI, R., and BLIGHT, A.R. (1977). Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord. Neuroscience 77, 553-562.
57. SMEETS, J.W., and KUNST, M.W. (1995). Severe poisoning by 4-aminopyridine in a body builder. Ned. Tijdschr. Geneeskd. 139, 2667-2669.
58. SMITS, R.C.F., EMMEN, H.H., BERTELSMANN, F.W., KULIG, B.M., VAN LOENEN, A.C., and POLMAN, C.H. (1994). The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology 44, 1701-1705.
59. SPYKER, D.A., LYNCH, S., SHABANOWITZ, J., and SINN, J.A. (1980). Poisoning with 4-aminopyridine: report of three cases. Clin. Toxicol. 16, 487-497.
60. STEFOSKI, D., DAVIS, F.A., FITZSIMMONS, W.E., LUSKIN, S.S., RUSH, J., and PARKHURST, G.W. (1991). 4-Aminopyridine in multiple sclerosis: prolonged administration. Neurology 41, 1344-1348.
61. STEFOSKI, D.F., DAVIS, F.A., FAUT, M., and SCHAUF, C.L. (1987). 4-Aminopyridine improves clinical signs in multiple sclerosis. Ann. Neurol. 21, 71-77.
62. STORK, C.M., and HOFFMAN, R.S. (1994). Characterization of 4-aminopyridine in overdose. J. Toxicol. Clin. Toxicol. 32, 584-587.
63. TARG, E.F., and KOCSIS, J.D. (1985). 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res. 328, 358-361.
64. VAN DIEMEN, H.A., POLMAN, C.H., VAN DONGEN, T.M., et al. (1992). The effect of 4-aminopyridine on the clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, crossover study. Ann. Neurol. 32, 123-130.
65. WAXMAN, S.G. (1993). Aminopyridines and the treatment of spinal cord injury. J. Neurotrauma 10, 19-24.